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Tuberculous Pericarditis
Picco José Miguel
Abstract
The pericardium formed by two layers, pleural and visceral, fulfills the role 
of keeping the heart in position and in turn acts as a barrier against infections. 
Their commitment may be due to a wide variety of rare diseases where the causes 
are usually idiopathic, inflammatory, neoplastic, traumatic, congenital, or infec-
tious. Within the latter they are of viral, fungal, and bacterial origin, being able 
to be caused by Mycobacteria. Tuberculous pericarditis is the entity in which 
inflammation of the pericardium is caused by Koch’s bacillus. The access route to 
it includes three mechanisms: (1) lymphatic; (2) hematogenous spread, mainly in 
immunocompetent patients; and (3) by direct contact from adjacent structures 
such as the lung and pleura. In immunocompetent patients, the condition is usually 
paucibacillary, with manifestation at the level of a single organ, while in immuno-
compromised patients, the rate of bacterial replication is high. Tuberculosis (TB) 
is a disease that is far from being eradicated today. Despite the great majority of 
cases in which pulmonary involvement is confirmed, a large number of patients 
suffer compromises from other organs. If tuberculous pericarditis is suspected, it is 
important to be able to establish an early diagnosis in order to achieve an adequate 
treatment as soon as possible.
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1. Introduction
Tuberculosis (TB) has decreased its incidence in the industrialized countries in 
the last 100 years; despite this it remains within the top 10 of infectious diseases 
that cause death (above HIV). Millions of people contract TB every year [1]. 
Tuberculous pericarditis, caused by Mycobacterium tuberculosis (Mtb), is a rare 
disease, observed in about 2% of people suffering from pulmonary tuberculosis and 
about 1% in autopsies of people who die from tuberculosis [2].
2. Epidemiology
According to the global report of TB 2018, it is estimated that about 10 million 
people developed the disease during 2017. Cases were reported in all countries 
and age groups, but the majority (90%) occurred in adults (>15 years old). Nearly 
9% of infected people were HIV carriers (72% in Africa). Two thirds of the cases 
were reported in eight countries: India (27%), China (9%), Indonesia (8%), the 
Philippines (6%), Pakistan (5%), Nigeria (4%), Bangladesh (4%), and South Africa 
(3%). Only 6% of the cases were reported in the European region and 3% in the 
region of the Americas [1].
Inflammatory Heart Diseases
2
3. Pathogenesis of tuberculous pericarditis
Tubercle bacilli access the pericardium via three mechanisms: (1) retrograde 
lymphatic spread from mediastinal, paratracheal, and peribronchial lymph nodes 
[3], (2) hematogenous spread (dominant in immunocompromised hosts) [4], and 
(3) direct contiguous spread from adjacent structures such as the lungs, pleura, 
and spine (infrequent) [3]. When the guest is immunocompetent, tuberculous 
pericardial disease is localized to the pericardial space. Usually in a paucibacillary 
condition, tubercle proteins trigger an important cell-mediated hypersensitivity 
response with T-helper cell (subtype 1) predominant cytokine release, leading to an 
inflammatory exudative effusion and its hemodynamic sequelae [5, 6]. The immune 
response to the viable acid-fast bacilli penetrating the pericardium is responsible 
for the morbidity associated with tuberculous pericarditis. In patients with dys-
functional immunity as occurred in HIV/AIDS, there is evidence that mycobacterial 
replication is active, bacillary loads are high, and the clinical manifestations of 
tuberculous pericarditis are related to the impact of the infectious and virulent 
nature of the Mtb itself in addition to the hemodynamic sequelae [4–7].
There are four pathological stages of tuberculous pericarditis: (1) fibrinous 
exudation, initial polymorphonuclear leukocytosis, abundant mycobacteria, and 
early granuloma formation with loose organization of macrophages and T cells; 
(2) serosanguineous effusion with a predominantly lymphocytic exudate with 
monocytes and foam cells; (3) absorption of effusion with organization of granu-
lomatous caseation and pericardial thickening caused by fibrin, collagenosis, and, 
ultimately, fibrosis; and (4) constrictive scarring. The fibrosis generated between 
the visceral pericardium and the parietal pericardium can calcify and adhere to the 
myocardium, generating a cuirass around the heart, preventing the correct diastolic 
filling, and generating the clinical syndrome of constrictive pericarditis [8].
Tuberculous pericarditis presents clinically in three forms: pericardial effusion, 
constrictive pericarditis, and a combination of effusion and constriction.
4. Pericardial effusion
The triad of severe pericarditic chest pain: a pericardial friction rub, widespread 
ST segment, and T-wave abnormalities; and PR segment depression typical of 
acute pericarditis is an uncommon clinical presentation of tuberculous pericarditis, 
accounting for only 3–8% of patients who present with tuberculous pericarditis [9]. 
The pericardial effusion begins as soon as the tubercle bacillus enters the pericardium 
and develops slowly and insidiously. Is characterized pathologically by polymorpho-
nuclear leukocytosis with abundant bacilli and granuloma formation, and is usually 
present with nonspecific systemic symptoms, such as fever, night sweats, fatigue, and 
weight loss. Chest pain, cough, and breathlessness are uncommon symptoms [10].
TB pericarditis should be considered in the evaluation of all cases of pericarditis 
without a rapidly self-limited course.
4.1 Diagnosis of pericardial effusion
ECG is abnormal in most cases of tuberculous pericardial effusion, usually in the 
form of nonspecific ST-T-wave changes. The presence of microvoltage (complexes 
<5 mm in limb leads and <10 mm in precordial leads) suggests a large pericardial 
effusion [11]. Chest radiograph usually shows an enlarged cardiac shadow in more 
than 90% of cases and demonstrates features of active pulmonary TB in 30% of 
cases and pleural effusion in 40–60% of cases (Figure 1) [12]. The advent and 
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accessibility of echocardiography have made it possible to diagnose the pericardial 
effusion when suspected; however, it does not determine the etiology. The presence 
of fibrinous strands on the visceral pericardium is typical but not specific for a 
tuberculous pathogenesis (Video 1, https://bit.ly/2JNuQdB) [13]. Computed tomog-
raphy of the chest shows typical changes in mediastinal lymph nodes (enlargement 
>10 mm with matting and hypodense centers and sparing of hilar lymph nodes) in 
almost 100% of cases [14].
4.2 Direct methods for the diagnosis of tuberculous pericarditis
The pericardial fluid is bloodstained in 80% of cases of tuberculous pericarditis, 
but malignant disease and the late effects of penetrating trauma may also cause 
bloody pericardial effusion, so confirmation of TB as the cause is important [15]. 
Tuberculous pericardial effusions are typically exudative and characterized by 
a high protein content and increased leukocyte count, with a predominance of 
lymphocytes and monocytes. Light’s criteria (whereby an exudate is defined as 
having one or more of the following: pleural fluid protein divided by serum protein 
>0.5, pleural fluid lactate dehydrogenase [LDH] divided by serum LDH >0.6, and/
or pleural fluid LDH level > 66% of the upper limit of normal for serum LDH) [16] 
is the most reliable diagnostic tool for identifying pericardial exudates.
The definitive diagnosis of tuberculous pericarditis should be established as 
soon as possible, by searching for the acid-alcohol bacilli resistant in sputum, lymph 
nodes, or pericardial fluid [17]. Culture of tubercle bacilli from pericardial fluid 
can be improved by inoculation of the fluid into double-strength liquid Kirchner 
Figure 1. 
Chest X-ray in front of a merchant marine patient who consulted due to progressive dyspnea for months of 
evolution. In the consultation, he presented signs of cardiac tamponade, so an echocardiogram (Video 1, https://
bit.ly/2JNuQdB) was performed with an evacuating pericardiocentesis of 3 liters of hematopurulent fluid. 
Bacteriological isolation was not obtained, but there was increased ADA activity.
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culture medium, resulting in a 75% yield, compared with a 53% yield with con-
ventional culture [18]. Pericardial biopsy specimens may also be used to diagnose 
tuberculous pericarditis. The polymerase chain reaction (PCR) has also been sug-
gested for detecting M. tuberculosis DNA in pericardial fluid [19]. The probability 
of obtaining a definitive bacteriological result is greatest when pericardial fluid and 
biopsy specimens are examined early in the effusive stage [18].
4.3 Indirect methods for the diagnosis of tuberculous pericarditis
The difficulty of carrying out the diagnosis of tuberculous pericarditis, associ-
ated with its high mortality without proper treatment, has led to the use of indirect 
methods. Indirect methods such as dosing activity of adenosine deaminase (ADA) 
in the pericardial fluid, with cut-off levels between 30 and 60 U/L of ADA activity, 
are suggestive of tuberculous pericarditis [20]. In areas of the high endemic level of 
tuberculosis, a cut-off level of ADA activity <35 presents a sensitivity of 90% and a 
specificity of 74% for diagnosis [21]. The utility of ADA activity in pericardial fluid 
was also demonstrated in HIV-positive patients, although in patients with severe 
CD4 lymphocyte depletion, the ADA levels observed are lower [22].
Very high levels of ADA in pericardial fluid have strong association with con-
strictive pericarditis [23].
The measurement of interferon gamma (IFN-γ) levels in the pericardial fluid 
also helps early diagnosis. Cut-off values >200 pg/L have a sensitivity of 92% and 
specificity of 100% for the diagnosis of TB [21].
In summary, the “definitive” diagnosis of tuberculous pericarditis is based on the 
presence of the tubercle bacillus in the pericardial fluid or proving it in the pericar-
dium biopsy and “probably” when there is evidence of tuberculosis elsewhere in the 
body and the presence of unexplained pericarditis, with high levels of ADA or good 
response to pharmacological treatment.
5. Treatment
Pharmacological treatment increases survival in tuberculous pericarditis, 
even in HIV-positive patients [24]. A regimen that includes rifampicin, isoniazid, 
pyrazinamide, and ethambutol for at least 2 months, followed by rifampicin and 
isoniazid (up to 6 months), proved to be effective in extrapulmonary tuberculosis 
[25]. Treatments beyond 6 months do not show better results, increasing cost and 
decreasing tolerance [26].
The treatment associated with corticosteroids would not be justified at pres-
ent, given that the evidence for its use is not the best [27]. Although the results are 
inconclusive, adding corticosteroids to treatment may have benefits on morbidity 
and re-experiences, but randomized controlled trials with sufficient numbers of 
HIV-positive and HIV-negative patients are needed [28].
It is obvious that if pericarditis is associated with severe pericardial effu-
sion, with hemodynamic compromise, the first treatment option associated with 
antituberculous treatment is drainage by subxiphoid puncture or by minimal 
thoracotomy.
6. Constrictive pericarditis
It is the most feared complication of tuberculous pericarditis; it is described in 
about 30% of patients, even in spite of antituberculous treatment and the use of 
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corticosteroids [29]. The clinical presentation can be variable, from asymptomatic 
patients and stress design to heart failure with preserved function, liver failure (due 
to retrograde passive congestion) with ascites, and generalized edema. The presence 
of pericardial knock, associated with protodiastolic murmur, splitting of the second 
heart sound, and Kussmaul’s sign (paradoxical increase in jugular venous pressure 
in inspiration), is frequent in constrictive pericarditis but difficult to detect by non-
experienced observers [30].
6.1 Diagnosis of constrictive pericarditis
Sometimes we can see a calcium shell surrounding the heart in the chest X-ray, 
but it is not the most frequent [31]. Other nonspecific radiographic findings are 
dilation of the superior vena cava [12].
In the electrocardiogram there are no specific signs, either atrial fibrillation, 
nonspecific alterations of repolarization (changes in the T wave), or complexes with 
low voltage.
The Doppler echocardiogram may show thickening of the pericardium; the pres-
ence of fibrin; restrictive transmitral filling pattern, associated with normal size of 
the cavities, in the absence of ventricular hypertrophy; and valvular insufficiency.
6.2 Treatment
The treatment must include antituberculous medication for 6 months. Consider 
pericardiectomy in all patients once antibiotic treatment has been instituted [32]. 
Surgery should be performed early if the patient presents hemodynamic deteriora-
tion (despite antituberculous treatment) [33] or if they present pericardial calcifi-
cations, which are markers of chronicity of the disease [34].
7. Effusive-constrictive pericarditis
It is the presence of increased intrapericardial pressure due to effusion and 
constriction of the visceral pericardium, which does not improve with pericardio-
centesis. The signs and symptoms are similar to those of constrictive pericarditis.
The treatment is pericardiectomy associated with antituberculous treatment for 
6 months.
8. Conclusions
Tuberculous pericarditis is a rare pathology in developed countries but frequent 
in developing countries. There is difficulty in the diagnosis due to low bacteriologi-
cal and histological results. The usefulness of indirect methods for diagnosis should 
be taken into account, especially in patients with torpid pericarditis. The presence 
of positive serology for HIV can modify the clinical presentation and the outcome 
of tuberculous pericarditis.
There is still a lack of sustainable evidence for the use of systemic corticosteroids 
in this pathology.
Pharmacological treatment should be performed for at least 6 months in all 
patients with tuberculous pericarditis, regardless of drainage or pericardiectomy.
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